NasdaqGS:SVRABiotechs
A Look At Savara (SVRA) Valuation After Expanded Hercules Funding Linked To MOLBREEVI Approval
Savara (SVRA) amended its loan agreement with Hercules Capital, giving it access to up to an additional $75 million if the FDA approves MOLBREEVI, its investigational therapy for autoimmune pulmonary alveolar proteinosis.
See our latest analysis for Savara.
Against the backdrop of the Hercules and royalty funding agreements, Savara’s 90 day share price return of 26.94% and 1 year total shareholder return of 90.18% indicate that momentum has been building despite recent shorter term share...